These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 28645089

  • 1. Drug Resistance Mechanism of L10F, L10F/N88S and L90M mutations in CRF01_AE HIV-1 protease: Molecular dynamics simulations and binding free energy calculations.
    Vasavi CS, Tamizhselvi R, Munusami P.
    J Mol Graph Model; 2017 Aug; 75():390-402. PubMed ID: 28645089
    [Abstract] [Full Text] [Related]

  • 2. Mechanism of drug resistance due to N88S in CRF01_AE HIV-1 protease, analyzed by molecular dynamics simulations.
    Ode H, Matsuyama S, Hata M, Hoshino T, Kakizawa J, Sugiura W.
    J Med Chem; 2007 Apr 19; 50(8):1768-77. PubMed ID: 17367119
    [Abstract] [Full Text] [Related]

  • 3. Exploring the drug resistance mechanism of active site, non-active site mutations and their cooperative effects in CRF01_AE HIV-1 protease: molecular dynamics simulations and free energy calculations.
    C S V, Tamizhselvi R, Munusami P.
    J Biomol Struct Dyn; 2019 Jul 19; 37(10):2608-2626. PubMed ID: 30051758
    [Abstract] [Full Text] [Related]

  • 4. Structural studies on molecular mechanisms of Nelfinavir resistance caused by non-active site mutation V77I in HIV-1 protease.
    Gupta A, Jamal S, Goyal S, Jain R, Wahi D, Grover A.
    BMC Bioinformatics; 2015 Jul 19; 16 Suppl 19(Suppl 19):S10. PubMed ID: 26695135
    [Abstract] [Full Text] [Related]

  • 5. Resistance mechanism revealed by crystal structures of unliganded nelfinavir-resistant HIV-1 protease non-active site mutants N88D and N88S.
    Bihani SC, Das A, Prashar V, Ferrer JL, Hosur MV.
    Biochem Biophys Res Commun; 2009 Nov 13; 389(2):295-300. PubMed ID: 19720046
    [Abstract] [Full Text] [Related]

  • 6. Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants.
    Kozísek M, Bray J, Rezácová P, Sasková K, Brynda J, Pokorná J, Mammano F, Rulísek L, Konvalinka J.
    J Mol Biol; 2007 Dec 07; 374(4):1005-16. PubMed ID: 17977555
    [Abstract] [Full Text] [Related]

  • 7. Understanding the HIV-1 protease nelfinavir resistance mutation D30N in subtypes B and C through molecular dynamics simulations.
    Soares RO, Batista PR, Costa MG, Dardenne LE, Pascutti PG, Soares MA.
    J Mol Graph Model; 2010 Sep 07; 29(2):137-47. PubMed ID: 20541446
    [Abstract] [Full Text] [Related]

  • 8. The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.
    Bandaranayake RM, Kolli M, King NM, Nalivaika EA, Heroux A, Kakizawa J, Sugiura W, Schiffer CA.
    J Virol; 2010 Oct 07; 84(19):9995-10003. PubMed ID: 20660190
    [Abstract] [Full Text] [Related]

  • 9. Resistant mechanism against nelfinavir of human immunodeficiency virus type 1 proteases.
    Ode H, Ota M, Neya S, Hata M, Sugiura W, Hoshino T.
    J Phys Chem B; 2005 Jan 13; 109(1):565-74. PubMed ID: 16851048
    [Abstract] [Full Text] [Related]

  • 10. Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.
    Bastys T, Gapsys V, Walter H, Heger E, Doncheva NT, Kaiser R, de Groot BL, Kalinina OV.
    Retrovirology; 2020 May 19; 17(1):13. PubMed ID: 32430025
    [Abstract] [Full Text] [Related]

  • 11. Molecular Dynamics Simulations of HIV-1 Protease Suggest Different Mechanisms Contributing to Drug Resistance.
    Wartha F, Horn AH, Meiselbach H, Sticht H.
    J Chem Theory Comput; 2005 Mar 19; 1(2):315-24. PubMed ID: 26641303
    [Abstract] [Full Text] [Related]

  • 12. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance.
    Muzammil S, Ross P, Freire E.
    Biochemistry; 2003 Jan 28; 42(3):631-8. PubMed ID: 12534275
    [Abstract] [Full Text] [Related]

  • 13. Systematic molecular dynamics, MM-PBSA, and ab initio approaches to the saquinavir resistance mechanism in HIV-1 PR due to 11 double and multiple mutations.
    Tzoupis H, Leonis G, Avramopoulos A, Mavromoustakos T, Papadopoulos MG.
    J Phys Chem B; 2014 Aug 14; 118(32):9538-52. PubMed ID: 25036111
    [Abstract] [Full Text] [Related]

  • 14. Drug-resistant molecular mechanism of CRF01_AE HIV-1 protease due to V82F mutation.
    Liu X, Xiu Z, Hao C.
    J Comput Aided Mol Des; 2009 May 14; 23(5):261-72. PubMed ID: 19219633
    [Abstract] [Full Text] [Related]

  • 15. Patterns of point mutations associated with antiretroviral drug treatment failure in CRF01_AE (subtype E) infection differ from subtype B infection.
    Ariyoshi K, Matsuda M, Miura H, Tateishi S, Yamada K, Sugiura W.
    J Acquir Immune Defic Syndr; 2003 Jul 01; 33(3):336-42. PubMed ID: 12843744
    [Abstract] [Full Text] [Related]

  • 16. Revealing the drug resistance mechanism of saquinavir due to G48V and V82F mutations in subtype CRF01_AE HIV-1 protease: molecular dynamics simulation and binding free energy calculations.
    C S V, Munusami P.
    J Biomol Struct Dyn; 2023 Feb 01; 41(3):1000-1017. PubMed ID: 34919029
    [Abstract] [Full Text] [Related]

  • 17. Structural Basis of Why Nelfinavir-Resistant D30N Mutant of HIV-1 Protease Remains Susceptible to Saquinavir.
    Prashar V, Bihani SC, Ferrer JL, Hosur MV.
    Chem Biol Drug Des; 2015 Sep 01; 86(3):302-8. PubMed ID: 25487655
    [Abstract] [Full Text] [Related]

  • 18. The impact of active site mutations of South African HIV PR on drug resistance: Insight from molecular dynamics simulations, binding free energy and per-residue footprints.
    Ahmed SM, Maguire GE, Kruger HG, Govender T.
    Chem Biol Drug Des; 2014 Apr 01; 83(4):472-81. PubMed ID: 24267738
    [Abstract] [Full Text] [Related]

  • 19. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S, Shah K.
    In Silico Biol; 2008 Apr 01; 8(5-6):427-47. PubMed ID: 19374129
    [Abstract] [Full Text] [Related]

  • 20. N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.
    Mitsuya Y, Winters MA, Fessel WJ, Rhee SY, Hurley L, Horberg M, Schiffer CA, Zolopa AR, Shafer RW.
    AIDS Res Hum Retroviruses; 2006 Dec 01; 22(12):1300-5. PubMed ID: 17209774
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.